These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

265 related articles for article (PubMed ID: 17845846)

  • 1. Design and conduct of phase II studies of targeted anticancer therapy: recommendations from the task force on methodology for the development of innovative cancer therapies (MDICT).
    Booth CM; Calvert AH; Giaccone G; Lobbezoo MW; Eisenhauer EA; Seymour LK
    Eur J Cancer; 2008 Jan; 44(1):25-9. PubMed ID: 17845846
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Endpoints and other considerations in phase I studies of targeted anticancer therapy: recommendations from the task force on Methodology for the Development of Innovative Cancer Therapies (MDICT).
    Booth CM; Calvert AH; Giaccone G; Lobbezoo MW; Seymour LK; Eisenhauer EA
    Eur J Cancer; 2008 Jan; 44(1):19-24. PubMed ID: 17890079
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Design and conduct of early clinical studies of two or more targeted anticancer therapies: recommendations from the task force on Methodology for the Development of Innovative Cancer Therapies.
    Seymour LK; Calvert AH; Lobbezoo MW; Eisenhauer EA; Giaccone G;
    Eur J Cancer; 2013 May; 49(8):1808-14. PubMed ID: 23428669
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An overview of the optimal planning, design, and conduct of phase I studies of new therapeutics.
    LoRusso PM; Boerner SA; Seymour L
    Clin Cancer Res; 2010 Mar; 16(6):1710-8. PubMed ID: 20215546
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeted agents: how to select the winners in preclinical and early clinical studies?
    Goodwin R; Giaccone G; Calvert H; Lobbezoo M; Eisenhauer EA
    Eur J Cancer; 2012 Jan; 48(2):170-8. PubMed ID: 22093946
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Improving the design of phase II trials of cytostatic anticancer agents.
    Stone A; Wheeler C; Barge A
    Contemp Clin Trials; 2007 Feb; 28(2):138-45. PubMed ID: 16843736
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Novel designs and end points for phase II clinical trials.
    Adjei AA; Christian M; Ivy P
    Clin Cancer Res; 2009 Mar; 15(6):1866-72. PubMed ID: 19276272
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Translation of innovative designs into phase I trials.
    Rogatko A; Schoeneck D; Jonas W; Tighiouart M; Khuri FR; Porter A
    J Clin Oncol; 2007 Nov; 25(31):4982-6. PubMed ID: 17971597
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Methodological approaches of clinical studies with targeted therapies].
    Penel N; Saleron J; Lansiaux A; Clisant S; Adenis A; Fournier C; Duhamel A; Bonneterre J
    Bull Cancer; 2008 Feb; 95(2):185-90. PubMed ID: 18304903
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Other paradigms: better treatments are identified by better trials: the value of randomized phase II studies.
    Sharma MR; Maitland ML; Ratain MJ
    Cancer J; 2009; 15(5):426-30. PubMed ID: 19826363
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase II clinical trial design: methods in translational research from the Genitourinary Committee at the Eastern Cooperative Oncology Group.
    Gray R; Manola J; Saxman S; Wright J; Dutcher J; Atkins M; Carducci M; See W; Sweeney C; Liu G; Stein M; Dreicer R; Wilding G; DiPaola RS
    Clin Cancer Res; 2006 Apr; 12(7 Pt 1):1966-9. PubMed ID: 16609005
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Review of phase II trial designs used in studies of molecular targeted agents: outcomes and predictors of success in phase III.
    El-Maraghi RH; Eisenhauer EA
    J Clin Oncol; 2008 Mar; 26(8):1346-54. PubMed ID: 18285606
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparing an experimental agent to a standard agent: relative merits of a one-arm or randomized two-arm Phase II design.
    Taylor JM; Braun TM; Li Z
    Clin Trials; 2006; 3(4):335-48. PubMed ID: 17060208
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Design and Conduct of Early Clinical Studies of Immunotherapy: Recommendations from the Task Force on Methodology for the Development of Innovative Cancer Therapies 2019 (MDICT).
    Smoragiewicz M; Adjei AA; Calvo E; Tabernero J; Marabelle A; Massard C; Tang J; de Vries EGE; Douillard JY; Seymour L;
    Clin Cancer Res; 2020 Jun; 26(11):2461-2465. PubMed ID: 32086344
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Randomized phase II designs in cancer clinical trials: current status and future directions.
    Lee JJ; Feng L
    J Clin Oncol; 2005 Jul; 23(19):4450-7. PubMed ID: 15994154
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase II clinical trials in oncology: are we hitting the target?
    Ang MK; Tan SB; Lim WT
    Expert Rev Anticancer Ther; 2010 Mar; 10(3):427-38. PubMed ID: 20214523
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Trial design for evaluation of novel targeted therapies.
    Farley J; Rose PG
    Gynecol Oncol; 2010 Feb; 116(2):173-6. PubMed ID: 19853899
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bivariate sequential designs for phase II trials.
    Conaway MR; Petroni GR
    Biometrics; 1995 Jun; 51(2):656-64. PubMed ID: 7662852
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Optimizing randomized phase II trials assessing tumor progression.
    Stone A; Wheeler C; Carroll K; Barge A
    Contemp Clin Trials; 2007 Feb; 28(2):146-52. PubMed ID: 16807129
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Oncology phase I trial design and conduct: time for a change - MDICT Guidelines 2022.
    Araujo D; Greystoke A; Bates S; Bayle A; Calvo E; Castelo-Branco L; de Bono J; Drilon A; Garralda E; Ivy P; Kholmanskikh O; Melero I; Pentheroudakis G; Petrie J; Plummer R; Ponce S; Postel-Vinay S; Siu L; Spreafico A; Stathis A; Steeghs N; Yap C; Yap TA; Ratain M; Seymour L
    Ann Oncol; 2023 Jan; 34(1):48-60. PubMed ID: 36182023
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.